Therefore, a concept of “synthetic lethality” has been suggested, in which it was established that the treatment of BRCA-deficient cancers with PARP inhibitors deprives BC cells of both BER and HR repair mechanisms, resulting in the arrest of the cell cycle with subsequent cell death8. Here, PARP1 is linked to cancer.